Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature

• Published in: Mycopathologia (1975) Vol. 186; no. 2; pp. 289 - 298
• Main Authors: Garg, Deepak, Muthu, Valliappan, Sehgal, Inderpaul Singh, Ramachandran, Raja, Kaur, Harsimran, Bhalla, Ashish, Puri, Goverdhan D., Chakrabarti, Arunaloke, Agarwal, Ritesh
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.05.2021; Springer Nature B.V
• Subjects: Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Alanine - analogs & derivatives; Alanine - therapeutic use; Amphotericin B; Antifungal agents; Antiviral Agents - therapeutic use; Aspergillosis; Biomedical and Life Sciences; Case Report; Case reports; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - therapy; Diabetes; Diabetes Complications; Diabetes mellitus; End-stage renal disease; Eukaryotic Microbiology; Fungal infections; Glucocorticoids; Glucocorticoids - therapeutic use; Humans; Immunosuppressive agents; Kidney diseases; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - therapy; Life Sciences; Literature reviews; Male; Medical Microbiology; Microbial Ecology; Microbiology; Middle Aged; Monoclonal antibodies; Mucormycosis; Mucormycosis - complications; Mucormycosis - microbiology; Mucormycosis - therapy; Plant Sciences; Rhizopus - isolation & purification; Risk Factors; Steroids; Systematic review; Tomography, X-Ray Computed; Treatment Outcome; CAPA; Dexamethasone; Diabetes; Tocilizumab; Zygomycosis; Mucorales

Severe coronavirus disease (COVID-19) is currently managed with systemic glucocorticoids. Opportunistic fungal infections are of concern in such patients. While COVID-19 associated pulmonary aspergillosis is increasingly recognized, mucormycosis is rare. We describe a case of probable pulmonary muco...